Drug Trial Radar · NCT07208461
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Oct 21, 2025
Primary completion
Mar 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Guangzhou Patronus Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, observer-blinded, placebo-controlled Phase Ⅱ clinical trial to evaluate the immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
Conditions
- Respiratory Syncytial Virus Infection Prevention
Interventions
Low dose antigen of LYB005 without A01B adjuvantBiological
0.5 mL per dose, containing a total of 30 μg antigen without A01B adjuvant.
Low dose antigen of LYB005 with A01B adjuvantBiological
0.5 mL per dose, containing a total of 30 μg antigen adjuvanted with A01B.
Middle dose antigen of LYB005 without A01B adjuvantBiological
0.5 mL per dose, containing a total of 60 μg antigen without A01B adjuvant.
Middle dose antigen of LYB005 with A01B adjuvantBiological
0.5 mL per dose, containing a total of 60 μg antigen adjuvanted with A01B.
High dose antigen of LYB005 without A01B adjuvantBiological
0.5 mL per dose, containing a total of 120 μg antigen without A01B adjuvant.
High dose antigen of LYB005 with A01B adjuvantBiological
0.5 mL per dose, containing a total of 120 μg antigen adjuvanted with A01B.
PlaceboBiological
0.5 mL 0.9% sodium chloride (normal saline) injection per dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- The geometric mean titer (GMT) of Neutralizing Antibodies Against RSV A and RSV BTime frame: 30 days after vaccination
- Geometric Mean Fold Rise (GMFR) for Neutralizing Antibodies Against RSV A and RSV BTime frame: 30 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Disease Control and Prevention of Dangyang City
Dangyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.